Ken Warrington, PhD joined GenScript Probio in 2020 as Head of Strategy & Innovation and a Sr. Director of Business Development supporting their Gene & Cell Therapy CMC services. Dr. Warrington served on the faculty at the University of Florida focused on AAV vector development and transitioned into industry where he has served lead technical operation and business development roles for global contract testing and manufacturing organizations. He is a co-founder and director of Lacerta Therapeutics and Chair of the Scientific Advisory Board at Biostem Life Sciences. He has broad expertise across the viral vector product development continuum from discovery through GMP-compliant manufacturing to support IND-enabling preclinical and early stage clinical programs.